RESCEU aims to investigate serious lung infections caused by respiratory syncytial virus (RSV) that particularly affect babies and older people, and those with weakened immune systems, including cancer patients and people with chronic lung diseases such as emphysema.
The Consortium aims to integrate and exploit existing knowledge and data to improve the way RSV-associated disease is monitored across Europe and to advise future vaccination programmes. Through the development of guidelines and active engagement with key stakeholders, RESCEU aims to ensure that future decisions on RSV prevention and treatment policies can be based on good evidence and made without undue delay. The group also aims to set up a framework to conduct Europe-wide trials of new medicines and vaccines to improve treatment – and even prevention – of the disease.
The RESCEU project has an initial budget of €29M distributed across 18 partner from universities, clinical centres, health organisations, and pharmaceutical companies, sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU).